Insider Buying: GlucoTrack, Inc. (NASDAQ:GCTK) Director Purchases 182,540 Shares of Stock

GlucoTrack, Inc. (NASDAQ:GCTK) Director Drew Sycoff acquired 182,540 shares of the company’s stock in a transaction dated Monday, April 22nd. The stock was acquired at an average cost of $1.26 per share, for a total transaction of $230,000.40. Following the completion of the purchase, the director now directly owns 2,951,258 shares in the company, valued at $3,718,585.08. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

GlucoTrack Stock Down 37.0 %

Shares of NASDAQ:GCTK opened at $0.48 on Thursday. The company has a debt-to-equity ratio of 0.06, a current ratio of 3.22 and a quick ratio of 3.22. The business’s 50-day moving average is $0.38 and its 200-day moving average is $0.28. GlucoTrack, Inc. has a 1 year low of $0.13 and a 1 year high of $1.00.

GlucoTrack (NASDAQ:GCTK) last announced its quarterly earnings data on Thursday, March 28th. The company reported ($0.10) earnings per share (EPS) for the quarter.

About GlucoTrack

GlucoTrack, Inc, a medical device company, focuses on designing, developing, and commercializing non-invasive glucose monitoring devices for use by people with diabetes in the United States. It develops GlucoTrack, a non-invasive blood glucose monitor that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain.